A yearlong clinical trial in more than a dozen countries reveals that once-a-week-Trulicity, used in conjunction with short acting insulin, not only improved blood sugar control for subjects with type 2 diabetes, but also curbed hypoglycemia compared to a standard treatment and reduced weight in trial subjects. Trulicity is in a class of treatments known as GLP-1 receptor agonists—short for glucagon-like peptide-1 receptor agonists.
By hypoglycemia he meant a blood sugar reading of 70 or less, or signs and symptoms of low blood sugar, or both. Milicevic estimated that 20 to 30 percent of all type 2 diabetics are currently being treated with insulin, while the other 70 to 80 percent take oral medications to stabilize their blood sugar.
Subjects using Trulicity reported they experienced some gastrointestinal side effects more commonly than those using Lantus.
While the results from the study were mostly positive for Trulicity, there is one major obstacle to more widespread use of GLP-1s that is affecting all such treatments, whether they are administered daily or weekly.
The Diabetes Media Foundation is a 501(c)(3) tax-exempt nonprofit media organization devoted to informing, educating, and generating community around living a healthy life with diabetes. Dec 2, 2014 By Monica Terire Leave a Comment Insulin pumps are not unheard of; most commonly employed for control of blood glucose levels in type 1 diabetes. Type 1 diabetes is a condition that arises due to loss of beta cells in the pancreas due to an autoimmune reaction.
The study was led by Doctor Ahmad Haidar, who is a part of the Institut de Recherches Cliniques de Montreal (IRCM) and the Division of Experimental Medicine, Department of Medicine at the McGill University . The artificial pump that these researchers developed contained two essential hormones: insulin and glucagon. This site complies to the HONcode standard for trustworthy health information: verify here. GLP-1 is a hormone in the body that gets released in the intestine during the stage of digestion when carbohydrates are absorbed, stimulating the release of insulin from pancreatic beta cells. For the trial, Trulicity was compared to insulin glargine, a once-daily injectable treatment, the most popular of which is Sanofi’s Lantus. Basal-bolus therapy is when a diabetic takes long acting insulin once a day to stabilize glucose levels while fasting, while also taking short-acting insulin before main meals to counteract increases in blood glucose levels from eating.
Between 16 and 17 percent of subjects on Trulicity (depending on the dose) experienced diarrhea, while between 18 and 26 percent suffered from nausea. Since beta cells are insulin producing cells, loss of insulin leads to a high glycemic index. We wanted to determine the usefulness of glucagon in the artificial pancreas, especially to prevent hypoglycemia, which remains the major barrier to reaching glycemic targets,” said Dr.
Basal-bolus therapy is thought by many to approximate the way in which a person without diabetes produces insulin.
Most of the trial’s 884 patients were from the United States, while others were from Europe, South America, and Asia. By contrast, 6 percent of subjects on Lantus experienced diarrhea and 3 percent of subjects reported nausea. The long term sequela include respiratory crisis associated with poor glycemic control, diabetic neuropathy and eye problems that lead to blindness.
Rabasa-Lhoret, who is a professor at the Department of Nutrition at the University of Montreal and Director of Obesity, Metabolism and Diabetes research clinic at the IRCM.
The artificial pancreas adapt to the body’s need and deliver the amount of insulin that is required to keep high levels of glucose in check.
However, if the blood glucose levels fall below the optimum value, the pancreas delivers the second hormone, glucagon which has the potential to combat hypoglycemia. Hence providing greater control over the glycemic index than the available conventional therapies.
The researchers are planning to test this invention over a larger scale to eliminate any problems and evaluate the benefits and risks better.
How does diabetes type 2 affect the pancreas|
January 15 2016
Zneel cfg 2010
Pictures of diabetes type 1 quiz